ALIVEGEN USA INC has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and Brazil. Its main competitors in its focus markets pharmaceuticals and biotechnology are CREATIVE PEPTIDES SWEDEN AB, IMCLONE SYSTEMS INC and MEDIMMUNE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 2 | |
#2 | WIPO (World Intellectual Property Organization) | 2 | |
#3 | Brazil | 1 | |
#4 | Canada | 1 | |
#5 | Israel | 1 | |
#6 | Republic of Korea | 1 | |
#7 | Mexico | 1 | |
#8 | Singapore | 1 | |
#9 | Taiwan | 1 | |
#10 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Han Hq | 8 |
#2 | Zhou Xiaolan | 8 |
#3 | Xiaolan Zhou | 3 |
#4 | Hq Han | 3 |
Publication | Filing date | Title |
---|---|---|
TW201827069A | Novel Hybrid ActRIIB Ligand Trap Proteins For Treating Muscle Wasting And Bone Disease | |
BR112017022658A2 | isolated protein, isolated nucleic acid molecule, recombinant vector, host cell, method of producing a hybrid actriib protein, pharmaceutical composition, methods of treating myostatin or activin-related disorders, muscle wasting disease, disease cardiovascular disease, metabolic disorders, cancer cells, kidney disease, inflammatory / autoimmune disease, fibrosis disease, anemia, pain, aging condition, bone disorders, muscle wasting or metabolic disorder or fibrotic or inflammatory or activin-related in individuals, and a method of inducing stem cell growth for tissue repair or organ regeneration in an individual |